PERTH, Australia – More patients with Pompe disease in New Zealand will now have access to Sanofi Genzyme's enzyme replacement therapy Myozyme (alglucosidase alfa), but not because the country's single payer will pay for the drug. Rather, Sanofi Genzyme, of Cambridge, Mass., part of Sanofi SA, has stepped in to provide the therapy for free to patients in New Zealand.